Andrew Wardley

19.8k citations

147 papers · 9.0k indexed · 6 hit papers · h-index 36

Impact in

Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
Cancer Research top 0.5%
- Breast Cancer Treatment Studies

Papers in

Cancer Research 66
- Breast Cancer Treatment Studies 58
Oncology 118
- Cancer Treatment and Pharmacology 65
- HER2/EGFR in Cancer Research 62
- Peptidase Inhibition and Analysis 10

Co-authors: David Miles Javier Cortés Helena Earl Mark E. Robson Judy E. Garber Michael Friedländer Susan M. Domchek Andrew Tutt
Journals: Journal of Clinical Oncology (43 papers)Cancer Research (20 papers)Annals of Oncology (16 papers)British Journal of Cancer (8 papers)Breast Cancer Research and Treatment (7 papers)
Partner nations: United Kingdom United States France

In The Last Decade

Andrew Wardley

144 papers receiving 8.8k citations

Hit Papers

6 papers align trajectories log scale

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer 2010 · 700 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2010 Journal of Clinical Oncology
2010 The Lancet
2010 Journal of Clinical Oncology
2009 Journal of Clinical Oncology
2007 Journal of Clinical Oncology
1997 Journal of Clinical Oncology

Peers

Countries citing papers authored by Andrew Wardley

Since Specialization

Citations

This map shows the geographic impact of Andrew Wardley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Wardley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Wardley more than expected).

Fields of papers citing papers by Andrew Wardley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Wardley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Wardley. The network helps show where Andrew Wardley may publish in the future.

Co-authors

The 25 scholars most cited alongside Andrew Wardley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew Wardley Line = papers co-authored together Andrew Wardley links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data PubMed ·Helena Earl, Louise Hiller, Janet Dunn, Dong Young Kim, Pierfranco Conté, Roberto D’Amico, Valentina Guarneri, Heikki Joensuu, Teppo Huttunen, Dora Hatzidaki, Vassilis Georgoulias, Jean Abraham, David Miles, David Cameron, Andrew Wardley, Xavier Pivot	2025	0
2	Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT) BMJ Open ·Rebecca Maier, Chris Plummer, Adetayo Kasim, Nasima Akhter, Emmanuel Ogundimu, 智子岡田, M. Geršic, Michael J. Stewart, Andrew Wardley, Geng Hong‐Lian, Eduardo Lozano Guzmán, Helen Oxenham, Alison Humphreys, Nicola Cresti, Mark Verrill, Richard Graham, Lisa Chang, Helen Hancock, David Austin	2022	3
3	Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge Cancer Treatment Reviews ·Christian Jackisch, Patricia Cortazar, Charles E. Geyer, Luca Gianni, Joseph Gligorov, D. A. Weiner, Edith A. Perez, Andreas Schneeweiß, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart	2021	12
4	LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer Annals of Oncology ·Helena Earl, Louise Hiller, Julie Dunn, Pierfranco Conté, Roberto D’Amico, Valentina Guarneri, Heikki Joensuu, Teppo Huttunen, Philipp Marheineke, James Abraham, David Cameron, D.W. Miles, Andrew Wardley, Gilles Romieu, M. Debled, Jhua de Oliveira Ferreira, Henrik Lindman, Judith Fraser, Ziyun Guang, Xavier Pivot	2021	14
5	278MO cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients Annals of Oncology ·هناء محمد زکي, D. Moore, Iurie Bulat, 亨有泉, 谢鸿恩, H-T. Arkenau, Richard D. Baird, Andrew Wardley, Rebecca Roylance, Masac Tatematsu, Jennifer Yum-Park, Tao Wan, Andrew P. Beelen, Jessica A. Sorrentino	2020	4
6	Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial Cancer ·José Pablo Leone, Bernard F. Cole, Meredith M. Regan, Beat Thürlimann, Alan S. Coates, Manuela Rabaglio, Anita Giobbie‐Hurder, Richard D. Gelber, Bent Ejlertsen, Vernon Harvey, Patrick Neven, István Láng, Hervé Bonnefoi, Andrew Wardley, Aron Goldhirsch, Angelo Di Leo, Marco Colleoni, Inês Vaz-Luís, Nancy U. Lin	2020	5
7	LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC) Annals of Oncology ·D.W. Miles, Joseph Gligorov, Fabrice André, David Cameron, Andreas Schneeweiß, C.H. Barrios, Binghe Xu, Andrew Wardley, Diego Kaen, Livia Andrade, Semiglazov Vf, Mattea Reinisch, Monika Patre, L. Morales, Kenneth Russell, Margarita Donica, Joyce O’Shaughnessy	2020	74
8	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) Clinical Cancer Research ·Nicholas C. Turner, Melinda L. Telli, Hope S. Rugo, Audrey Mailliez, Johannes Ettl, Eva‐Maria Grischke, Lida A. Mina, Judith Balmañà, Peter A. Fasching, Sara A. Hurvitz, Andrew Wardley, Colombe Chappey, Alison L. Hannah, Mark E. Robson	2018	88
9	Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results BMC Cancer ·Louise Hiller, Janet Dunn, Shrushma Loi, Anne-Laure Vallier, Loes Hoebers, David Cameron, David Miles, Andrew Wardley, Helena Earl	2018	5
10	Work Productivity in HER2 Positive Breast Cancer: A Comparison of Patients Across Stages of Early and Metastatic Disease Value in Health ·Mark Verrill, Peter Schmid, José Miguel Maldonado, V.P. Swapna, William Kurenty, P Culotta, Carolina Sayuri Arashiro, Hendrick Gao-Min Lim, Andrew Wardley	2017	1
11	A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) Annals of Oncology ·Giuseppe Curigliano, Sibylle Loibl, Volkmar Müller, Xavier Pivot, Andrew Wardley, David Cameron	2016	1
12	Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer Journal of Clinical Oncology ·José Baselga, Patricia Gómez, Richard Greil, Sofía Braga, Miguel Ángel Climent, Andrew Wardley, Bella Kaufman, Salomon M. Stemmer, António Pêgo, Arlene Chan, J. Goeminne, Marie-Pascale Graas, Megan Kennedy, Eva María Ciruelos Gil, Andreas Schneeweiß, Angela Zubel, Jutta Groos, Helena Melezínková, Ahmad Awada	2013	298
13	AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer Journal of Clinical Oncology ·Luca Gianni, Gilles Romieu, М. Р. Личиницер, Sérgio Serrano, Mauro Mansutti, Xavier Pivot, Paola Mariani, Fabrice André, Arlene Chan, Oleg Lipatov, Stephen Chan, Andrew Wardley, Richard Greil, N. Moore, Ae Kyung Kim, Céline Pallaud, Semiglazov Vf	2013	199
14	CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01) The Lancet Oncology ·Bernhard C. Pestalozzi, Eileen Holmes, Evandro de Azambuja, Otto Metzger, Andrés Alejandro Ocampo Arbeláez, Jie Zhu, István Láng, Andrew Wardley, Mikhail Lichinitser, 李心峰, Volkmar Müller, David Dodwell, Richard D. Gelber, Martine Piccart, David Cameron	2013	142
15	Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer Breast Cancer Research and Treatment ·Ruth Board, Andrew Wardley, J. Michael Dixon, Anne Armstrong, Sacha J. Howell, Lorna Renshaw, Emma Donald, Alastair Greystoke, Malcolm Ranson, Andrew Hughes, Caroline Dive	2010	165
16	Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial Annals of Oncology ·L. Mauriac, Aparna Keshaviah, Marc Debled, Henning T. Mouridsen, John Forbes, Beat Thürlimann, R. Paridaens, Alain Monnier, István Láng, Andrew Wardley, Jean‐Marie Nogaret, RD Gelber, Monica Castiglione‐Gertsch, K.N. Price, Alan S. Coates, Ian Smith, Giuseppe Viale, Manuela Rabaglio, M. Wolf, Aron Goldhirsch	2007	106
17	Does HER2 overexpression affect response to endocrine therapy in advanced cancer? Nature Clinical Practice Oncology ·Andrew Wardley, Anthony Howell	2006	1
18	Fulvestrant (‘Faslodex’): Clinical experience from the Compassionate Use Programme Cancer Treatment Reviews ·Guenther G. Steger, Sonal Ojha, Sérgio D. Simon, Aňa Lluch, Hun Chan Lee, Bella Kaufman, Andrew Wardley, L. Mauriac	2005	18
19	Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration British Journal of Cancer ·Andrew Wardley, N. Davidson, Peter Barrett‐Lee, Martina Singer, Janine Mansi, David Dodwell, Robert L. Murphy, Tshela E. Mason, David Cameron	2005	121
20	The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone British Journal of Cancer ·Andrew Wardley, Gordon C. Jayson, Juan Miguel Fernández Campoy, Michael Venning, P. Ackrill, J H Scarffe	1998	27

About Andrew Wardley

Andrew Wardley is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 147 papers that have together received 9.0k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (65 papers), HER2/EGFR in Cancer Research (62 papers), Breast Cancer Treatment Studies (58 papers), Advanced Breast Cancer Therapies (46 papers), Estrogen and related hormone effects (23 papers), Brain Metastases and Treatment (10 papers), Peptidase Inhibition and Analysis (10 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). The work is most often cited by research in Oncology (6.8k citations), Cancer Research (2.4k citations), Pulmonary and Respiratory Medicine (3.2k citations), Genetics (1.7k citations) and Radiology, Nuclear Medicine and Imaging (1.2k citations). Andrew Wardley has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include David Miles, Javier Cortés, Helena Earl, Mark E. Robson, Judy E. Garber, Michael Friedländer, Susan M. Domchek, Andrew Tutt, Banu Arun and Gillian Mitchell. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, British Journal of Cancer and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact